Literature DB >> 7007488

Responses of volunteers to inactivated influenza virus vaccines.

R Jennings, C W Potter, P M Massey, B I Duerden, J Martin, A M Bevan.   

Abstract

Three different types of bivalent influenza virus vaccine, a whole virus, an aqueous-surface-antigen vaccine and an adsorbed-surface-antigen vaccine were tested at three dosage levels in volunteers primed with respect to only one of the haemagglutinin antigens present in the vaccines. The local and systemic reactions to all three vaccine types were mild in nature and, following first immunization, the aqueous-surface-antigen vaccine was the least reactogenic. The serum haemagglutination-inhibiting antibody response to the A/Victoria/75 component of the vaccines to which the volunteer population was primed, was greatest following immunization with the aqueous-surface-antigen vaccine; the greatest antibody response to the A/New Jersey/76 component of the vaccines was observed following immunization with whole virus vaccine.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7007488      PMCID: PMC2134056          DOI: 10.1017/s0022172400068698

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  26 in total

1.  A new, surface-antigen-adsorbed influenza virus vaccine. I. Studies on immunogenicity in hamsters.

Authors:  R Jennings; C W Potter; C McLaren; M Brady
Journal:  J Hyg (Lond)       Date:  1975-12

2.  Human febrile response to influenza virus or its ether isolated hemagglutinins.

Authors:  F B Brandon; C D Barrett; A E Hook; G O Lease
Journal:  Proc Soc Exp Biol Med       Date:  1967-07

3.  Comparative trial of influenza vaccines. II. Adverse reactions in children and adults.

Authors:  D W Barry; R E Mayner; H D Hochstein; R C Dunlap; S C Rastogi; J E Hannah; R J Blackburn; J L Sullivan; R J Gerety
Journal:  Am J Epidemiol       Date:  1976-07       Impact factor: 4.897

4.  A new subunit influenza vaccine: acceptability compared with standard vaccines and effect of dose on antigenicity.

Authors:  F L Ruben; G G Jackson
Journal:  J Infect Dis       Date:  1972-06       Impact factor: 5.226

5.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses.

Authors:  D Hobson; R L Curry; A S Beare; A Ward-Gardner
Journal:  J Hyg (Lond)       Date:  1972-12

6.  Influenza vaccine: split-product versus whole-virus types--How do they differ.

Authors:  P A Gross; F A Ennis
Journal:  N Engl J Med       Date:  1977-03-10       Impact factor: 91.245

7.  From the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the Center for Disease Control, and the Bureau of Biologics of the Food and Drug Administration. Summary of clinical trials of influenza vaccines--II.

Authors:  P F Wright; R Dolin; J R La Montagne
Journal:  J Infect Dis       Date:  1976-12       Impact factor: 5.226

8.  An adsorbed surface-antigen influenza vaccine and its serological activity in volunteers.

Authors:  M I Brady; I G Furminger; P B Stones
Journal:  Postgrad Med J       Date:  1976-06       Impact factor: 2.401

9.  Reactions and serologic responses in young children and infants after administration of inactivated monovalent influenza A vaccine.

Authors:  W M Marine; C Stuart-Harris
Journal:  J Pediatr       Date:  1976-01       Impact factor: 4.406

10.  A surface antigen influenza vaccine. 1. Purification of haemagglutinin and neuraminidase proteins.

Authors:  M I Brady; I G Furminger
Journal:  J Hyg (Lond)       Date:  1976-10
View more
  14 in total

1.  Developing vaccines against pandemic influenza.

Authors:  J M Wood
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-12-29       Impact factor: 6.237

2.  The IgA and subclass IgG responses and protection in mice immunised with influenza antigens administered as ISCOMS, with FCA, ALH or as infectious virus.

Authors:  E T Ben Ahmeida; R Jennings; M Erturk; C W Potter
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

3.  Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies.

Authors:  W E Beyer; A M Palache; R Kerstens; N Masurel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

Review 4.  Emerging respiratory viruses: challenges and vaccine strategies.

Authors:  Laura Gillim-Ross; Kanta Subbarao
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

5.  Antibody response and persistence in volunteers following immunization with varying dosages of a trivalent surface antigen influenza virus vaccine.

Authors:  R Jennings; T L Smith; A R Mellersh; A Clark; R C Spencer; C W Potter
Journal:  J Hyg (Lond)       Date:  1985-02

6.  Use of the enzyme-linked immunosorbent assay (ELISA) for the estimation of serum antibodies in an influenza virus vaccine study.

Authors:  R Jennings; T Smith; C W Potter
Journal:  Med Microbiol Immunol       Date:  1981       Impact factor: 3.402

7.  A comparison of adverse effects of two influenza vaccines, and the influence on subsequent uptake.

Authors:  M P Ryan; A F MacLeod
Journal:  J R Coll Gen Pract       Date:  1984-08

8.  Sequential infection or immunization of ferrets with a series of influenza A (H3N2) strains (report to the Medical Research Council's Sub-Committee on influenza Vaccines (CDVIP/IV)).

Authors:  C W Potter; R Jennings; M J Ali; J M Wood; U Dunleavy; D A Tyrrell
Journal:  Epidemiol Infect       Date:  1987-10       Impact factor: 2.451

9.  Interpretation of responses and protective levels of antibody against attenuated influenza A viruses using single radial haemolysis.

Authors:  R Al-Khayatt; R Jennings; C W Potter
Journal:  J Hyg (Lond)       Date:  1984-10

10.  A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection.

Authors:  N Masurel; J Laufer
Journal:  J Hyg (Lond)       Date:  1984-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.